High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

Silk, AW; Kaufman, HL; Curti, B; Mehnert, JM; Margolin, K; McDermott, D; Clark, J; Newman, J; Bommareddy, PK; Denzin, L; Najmi, S; Haider, A; Shih, WC; Kane, MP; Zloza, A

FRONTIERS IN ONCOLOGY, 2020; 9 ():

Abstract

High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combinat......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索